文献速递乳腺癌放疗放疗物理与技术

乳腺癌放疗后NT-proBNP纵向变化及与心功能障碍的关联

Longitudinal changes in NT-proBNP after breast cancer radiotherapy: clinical determinants of its trajectory and association with cardiac dysfunction (BACCARAT study).
PubMed 文献 · Clin Transl Radiat Oncol · 2026-06-03

该研究纳入101例未接受化疗的乳腺癌辅助放疗患者,纵向监测NT-proBNP至24个月。NT-proBNP在放疗结束及6个月时稳定,24个月时较基线升高16%。高胆固醇血症、中度低分割放疗(20×2.35 Gy)及芳香化酶抑制剂治疗与24个月NT-proBNP升高独立相关;24个月NT-proBNP>400 ng/L与癌症治疗相关心功能障碍(CTRCD)相关。

要点

  • 乳腺癌放疗后24个月NT-proBNP较基线升高16%(β=0.147,p<0.0001)。
  • 高胆固醇血症、20×2.35 Gy分割方案及芳香化酶抑制剂与NT-proBNP升高独立相关。
  • 24个月NT-proBNP>400 ng/L与CTRCD相关(OR=6.5,95%CI 1.24-33.85;p=0.027)。

核心结论

  • 乳腺癌放疗后2年NT-proBNP升高,与基线水平、心脏代谢因素、放疗分割方案及内分泌治疗相关。
  • NT-proBNP升高有助于识别亚临床心功能障碍高风险患者,支持心脏肿瘤学监测中的纵向生物标志物监测。

研究设计与样本

  • 前瞻性纵向队列研究(BACCARAT研究),纳入101例接受辅助放疗、未接受化疗的乳腺癌患者。
  • 在放疗前、放疗结束时、6个月及24个月测量NT-proBNP,并行纵向超声心动图检查。
  • 采用线性混合效应模型分析NT-proBNP轨迹相关因素,采用逻辑回归评估NT-proBNP与CTRCD的关联。

主要发现

  • NT-proBNP在放疗结束及6个月时保持稳定,24个月时较基线升高16%(β=0.147,p<0.0001)。
  • 基线NT-proBNP与随访水平强烈相关。
  • 高胆固醇血症(β=0.252,p=0.01)、中度低分割放疗20×2.35 Gy(β=0.372,p=0.0008)及芳香化酶抑制剂治疗(β=0.258,p=0.019)与24个月NT-proBNP升高独立相关,而心脏剂量指标无显著关联。

关键数值与推荐

  • CTRCD依据2022 ESC心脏肿瘤学指南定义。
  • 24个月NT-proBNP>400 ng/L与CTRCD的OR=6.5(95%CI 1.24-33.85;p=0.027)。

临床怎么用

  • 对接受辅助放疗的乳腺癌患者,尤其合并高胆固醇血症、采用20×2.35 Gy分割方案或接受芳香化酶抑制剂治疗者,可考虑纵向监测NT-proBNP。
  • 24个月NT-proBNP>400 ng/L提示亚临床心功能障碍风险升高,可辅助心脏肿瘤学随访决策。

局限性

  • 研究仅纳入未接受化疗的乳腺癌患者,结论外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: Radiotherapy (RT) for breast cancer (BC) may induce subclinical myocardial injury. Longitudinal trajectories of N-terminal pro-B-type natriuretic peptide (NT-proBNP), a biomarker of myocardial stress, remain insufficiently characterized. We aimed to assess changes in NT-proBNP over 2 years after RT, identify clinical and treatment-associated factors, and evaluate associations with cancer therapy-related cardiac dysfunction (CTRCD). METHODS: NT-proBNP was measured before RT, at RT completion, and at 6 and 24 months among 101 BC patients treated with adjuvant RT without chemotherapy. Echocardiography was performed longitudinally, and CTRCD was defined according to 2022 ESC Cardio-Oncology guidelines. Factors associated with NT-proBNP trajectories were analyzed using linear mixed-effects models. Logistic regression assessed associations between NT-proBNP and CTRCD. RESULTS: NT-proBNP remained stable at the end of RT and at 6 months but increased at 24 months (β = 0.147, p < 0.0001; +16%). Baseline NT-proBNP was strongly associated with follow-up levels. Hypercholesterolemia (β = 0.252, p = 0.01), slightly moderate hypofractionated RT (20 × 2.35 Gy; β = 0.372, p = 0.0008), and aromatase inhibitor therapy (β = 0.258, p = 0.019) were independently associated with higher NT-proBNP at 24 months, whereas cardiac dose metrics were not. Seventeen patients developed CTRCD. NT-proBNP > 400 ng/L at 24 months was associated with CTRCD (OR = 6.5, 95% CI 1.24-33.85; p = 0.027). CONCLUSION: NT-proBNP increased 2 years after breast RT and was associated with baseline level, cardiometabolic, RT fractionation, and endocrine factors. Elevated NT-proBNP could help to identify BC patients at higher risk of subclinical cardiac dysfunction, supporting longitudinal biomarker monitoring in cardio-oncology surveillance.

来源:Clin Transl Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Locquet M, Jimenez G, Camilleri J, et al. Longitudinal changes in NT-proBNP after breast cancer radiotherapy: clinical determinants of its trajectory and association with cardiac dysfunction (BACCARAT study). Clin Transl Radiat Oncol. 2026. PMID: 42290894. doi:10.1016/j.ctro.2026.101213

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。